Neuravi Introduces Collaborative Clot Research Initiative at ESMINT

September 5, 2014—Neuravi, an Ireland-based developer of innovative stroke therapy, announced the Neuravi Thromboembolic Initiative (NTI). The NTI brings together Neuravi engineers with clinicians and researchers from leading international institutions in an effort to deepen the understanding of the mechanical properties of clot and occlusion dynamics, with the goal of improving the physician’s ability to restore flow in acute ischemic stroke.

The announcement was made during “The Science of Clot” workshops at the 6^th ESMINT Congress of the European Society of Minimally Invasive Neurological Therapy in Nice, France. The ESMINT conference gathers leaders in minimally invasive neurological therapy from across Europe.

According to the company, the NTI workshops featured a presentation by Anastasios Mpotsaris, MD, of Uniklinik Köln in Germany, as well as interactive hands-on sessions with engineers exploring clot characterization, the dynamics of occlusion formation and clot-device interactions, and any potential implications for revascularization.

In the company’s press release, Prof. Laurent Pierot, MD, President of the ESMINT Congress, commented, “One of the goals of ESMINT is to advance the practice of neurointervention through the support of research, education, and training. Currently, there is a growing interest in identifying different clots and in understanding how different clot characteristics may impact treatment in acute ischemic stroke. The NTI workshops will help in these efforts.”

Neuravi’s initial technology platform, the EmboTrap revascularization device, addresses acute ischemic stroke. The EmboTrap received European CE Mark approval in 2013 and is not yet available for use in the United States, advised the company.